<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32293029</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2362</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of clinical investigation</Title><ISOAbbreviation>Eur J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>The NGS technology for the identification of genes associated with the ALS. A systematic review.</ArticleTitle><Pagination><StartPage>e13228</StartPage><MedlinePgn>e13228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/eci.13228</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">More than 30 causative genes have been identified in familial and sporadic amyotrophic lateral sclerosis (ALS). The next-generation sequencing (NGS) is a powerful and groundbreaking tool to identify disease-associated variants. Despite documented advantages of NGS, its diagnostic reliability needs to be addressed in order to use this technology for specific routine diagnosis.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Literature database was explored to identify studies comparing NGS and Sanger sequencing for the detection of variants causing ALS. We collected data about patients' characteristics, disease type and duration, NGS and Sanger properties.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">More than 200 bibliographic references were identified, of which only 14 studies matching our inclusion criteria. Only 2 out of 14 studies compared results of NGS analysis with the Sanger sequencing. Twelve studies screened causative genes associated to ALS using NGS technologies and confirmed the identified variants with Sanger sequencing. Overall, data about more 2,000 patients were analysed. The number of genes that were investigated in each study ranged from 1 to 32, the most frequent being FUS, OPTN, SETX and VCP. NGS identified already known mutations in 21 genes, and new or rare variants in 27 genes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NGS seems to be a promising tool for the diagnosis of ALS in routine clinical practice. Its advantages are represented by an increased speed and a lowest sequencing cost, but patients' counselling could be problematic due to the discovery of frequent variants of unknown significance.</AbstractText><CopyrightInformation>&#xa9; 2020 Stichting European Society for Clinical Investigation Journal Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pecoraro</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-1800-0936</Identifier><AffiliationInfo><Affiliation>Laboratory of Toxycology and Advanced Diagnostics, Department of Laboratory Medicine and Pathology, Ospedale Civile S. Agostino Estense, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9244-9782</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Ospedale Civile S. Agostino Estense, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carone</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Toxycology and Advanced Diagnostics, Department of Laboratory Medicine and Pathology, Ospedale Civile S. Agostino Estense, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9579-5341</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, ALS Center "Rita Levi Montalcini", University of Torino, Torino, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza, Torino, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Neuroscience Institute of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0002-3010-8851</Identifier><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trenti</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8093-4011</Identifier><AffiliationInfo><Affiliation>Laboratory of Toxycology and Advanced Diagnostics, Department of Laboratory Medicine and Pathology, Ospedale Civile S. Agostino Estense, Modena, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 AG999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Clin Invest</MedlineTA><NlmUniqueID>0245331</NlmUniqueID><ISSNLinking>0014-2972</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064251">Multifunctional Enzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C409460">OPTN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C484368">SETX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="C000614178">VCP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="D000074405">Valosin Containing Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="Y">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064251" MajorTopicYN="N">Multifunctional Enzymes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="Y">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074405" MajorTopicYN="N">Valosin Containing Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyothrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">evidence</Keyword><Keyword MajorTopicYN="N">gene detection</Keyword><Keyword MajorTopicYN="N">next-generation sequencing</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32293029</ArticleId><ArticleId IdType="mid">NIHMS1795476</ArticleId><ArticleId IdType="pmc">PMC9008463</ArticleId><ArticleId IdType="doi">10.1111/eci.13228</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis N, Galvez-Jimenez N. Epidemiology and pathogenesis of amyothrophic lateral sclerosis. UptoDate. 2018.</Citation></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;20(3):17085.</Citation><ArticleIdList><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88:540&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: a review. J Neurol Sci. 2019;399:217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R, Kapogiannis D, Huey ED, Momeni P. FTD and ALS: a tale of two diseases. Curr Alzheimer Res. 2011; 8(3):273&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3801195</ArticleId><ArticleId IdType="pubmed">21222600</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD:disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroppo P, Camuzat A, Guillot-Noel L, et al. Defining the spectrum of frontotemporal dementias associated with TARDBP mutations. Neurol Genet. 2016;2:e80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882769</ArticleId><ArticleId IdType="pubmed">27280171</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Pioro EP, Boehringer A, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014;17:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multi system proteinopathy and ALS. Nature. 2013;495:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res. 2012;1462:40&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">22261247</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Nicholson AM, Sarkar M, et al. TIA1 mutations in amyotrophic lateral sclerosis and frontotemporal dementia promote phase separation and alter stress granule dynamics. Neuron. 2017;95(808&#x2013;816):e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576574</ArticleId><ArticleId IdType="pubmed">28817800</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell NE, Lambert-Smith IA, Warraich ST, et al. Distinct partitioning of ALS associated TDP-43, FUS and SOD1 mutants into cellular inclusions. Sci Rep. 2015;5:13416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544019</ArticleId><ArticleId IdType="pubmed">26293199</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahheydari H, Ragagnin A, Walker AK, et al. Protein quality control and the amyotrophic lateral sclerosis/Frontotemporal dementia continuum. Front Mol Neurosci. 2017;10:119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5423993</ArticleId><ArticleId IdType="pubmed">28539871</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68:1440&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Monahan Z, Shewmaker F, Pandey UB. Stress granules at the intersection of autophagy and ALS. Brain Res. 2016;1649(Pt B): 189&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055418</ArticleId><ArticleId IdType="pubmed">27181519</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C. Relationship between C9orf72 repeat size and clinical phenotype. Curr Opin Genet Dev. 2017;44:117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">28319737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Zhang P, Kim HJ, et al. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167(3):774&#x2013;788.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi B, Hartmann H, May S, et al. Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD. Hum Mol Genet. 2017;26:790&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409121</ArticleId><ArticleId IdType="pubmed">28040728</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018;97(1268&#x2013;1283):e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013;98:236&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3841808</ArticleId><ArticleId IdType="pubmed">23986538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15:733&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098820</ArticleId><ArticleId IdType="pubmed">23887774</ArticleId></ArticleIdList></Reference><Reference><Citation>Strom SP, Lee H, Das K, et al. Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory. Genet Med. 2014;16(7):510&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4079763</ArticleId><ArticleId IdType="pubmed">24406459</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genet Med. 2006;8:448&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">16845278</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK, Dilliott AA, Ghani M, et al. The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration. NPJ Genom Med. 2016;1:16032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5685311</ArticleId><ArticleId IdType="pubmed">29263818</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein O, Nayshool O, Nefussy B, et al. OPTN 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes. Neurology. 2016;86:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4773945</ArticleId><ArticleId IdType="pubmed">26740678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Oh KW, Kwon MJ, et al. Identification of mutations in Korean patients with amyotrophic lateral sclerosis using multigene panel testing. Neurobiol Aging. 2016;37:209.e9&#x2013;209.e16.</Citation><ArticleIdList><ArticleId IdType="pubmed">26601740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YE, Oh KW, Noh MY, et al. Genetic and functional analysis of TBK1 variants in Korean patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2017;50:170.e1&#x2013;170.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamp M, Origone P, Geroldi A, et al. Twenty years of molecular analyses in amyotrophic lateral sclerosis: genetic landscape of Italian patients. Neurobiol Aging. 2018;66:179.e5&#x2013;179.e16.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525178</ArticleId></ArticleIdList></Reference><Reference><Citation>Leblond CS, Gan-Or Z, Spiegelman D, et al. Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2016;37:209.e17&#x2013;209.e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26493020</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZJ, Li HF, Tan GH, et al. Identify mutation in amyotrophic lateral sclerosis cases using HaloPlex target enrichment system. Neurobiol Aging. 2014;35:2881.e11&#x2013;2881.e15.</Citation><ArticleIdList><ArticleId IdType="pubmed">25109764</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangi G, Lattante S, Doronzio PN, et al. Matrin 3 variants are frequent in Italian ALS patients. Neurobiol Aging. 2017;49:218.e1&#x2013;218.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28029397</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S, Shatunov A, Sproviero W, et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140(6):1611&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5445258</ArticleId><ArticleId IdType="pubmed">28430856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, Sone J, Atsuta N, et al. Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiol Aging. 2016;39(219):e1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26742954</ArticleId></ArticleIdList></Reference><Reference><Citation>Narain P, Pandey A, Gupta S, Gomes J, Bhatia R, Vivekanandan P. Targeted next-generation sequencing reveals novel and rare variants in Indian patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2018:71:265.e9&#x2013;265.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">29895397</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A, Niihori T, Warita H, et al. Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiol Aging. 2017;53:194.e1&#x2013;194.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28160950</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripolszki K, T&#xf6;r&#xf6;k D, Gouden&#xe8;ge D, et al. High-throughput sequencing revealed a novel SETX mutation in a Hungarian patient with amyotrophic lateral sclerosis. Brain Behav. 2017;7:e00669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390843</ArticleId><ArticleId IdType="pubmed">28413711</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfc;rk M, Schr&#xf6;der R, Khuller K, et al. Genetic analysis of VCP and WASHcomplexgenes in a German cohort of sporadic ALS-FTD patients. Neurobiol Aging. 2017;56:213.e1&#x2013;213.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28551275</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Doyle C, Chi&#xf2; A, Traynor BJ. Use of genetic testing in amyotrophic lateral sclerosis by neurologists. JAMA Neurol. 2017;74:125&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112760</ArticleId><ArticleId IdType="pubmed">27893008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowicka N, Juranek J, Juranek JK, Wojtkiewicz J. Risk factors and emerging therapies in amyotrophic lateral sclerosis. Int J Mol Sci. 2019;20:2616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600314</ArticleId><ArticleId IdType="pubmed">31141951</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G, Guarnaccia M, Spampinato AG, et al. Integrative multi-omic analysis identifies new drivers and pathways in molecularly distinct subtypes of ALS. Sci Rep. 2019;9:9968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6620285</ArticleId><ArticleId IdType="pubmed">31292500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajiwara K, Berson EL, Dryja TP. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science. 1994:264:1604&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pubmed">8202715</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C90RF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C90RF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrizaila N, Sobue G, Kuwabara S, et al. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016;87:821&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">27093948</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Piccininni M. Amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference. Neuroepidemiology. 2019;52:93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">30602169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner KN, Nagaraja H, Allain DC, Quick A, Kolb S, Roggenbuck J. Patients with amyotrophic lateral sclerosis have high interest in and limited access to genetic testing. J Genet Courts. 2017;26:604&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">27761850</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Shaw PJ, et al. Safety, PK, PD, and exploratory efficacy in single and multiple dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS. American Academy of Neurology. 2019. Accessed May 4, 2019.</Citation></Reference><Reference><Citation>Benatar M, Stanislaw C, Reyes E, et al. Presymptomatic ALS genetic counseling and testing: Experience and recommendations. Neurology. 2016;86:2295&#x2013;2302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4909562</ArticleId><ArticleId IdType="pubmed">27194384</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook A, Williams K, Adams L, Blair I, Rowe DB. Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:475&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">28585888</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Chi&#xf2; A. Genetic counselling: psychological impact and concern. In: Pagnini F, Simmons Z, eds. Amyotrophic Lateral Sclerosis. Understanding and Optimizing Quality of Life and Psychological Well-Being. New York: NY: Oxford University Press; 2018: 89&#x2013;100.</Citation></Reference><Reference><Citation>Johansen Taber KA, Dickinson BD, Wilson M. The promise and challenges of next-generation genome sequencing for clinical care. JAMA Intern Med. 2014:174:275&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">24217348</ArticleId></ArticleIdList></Reference><Reference><Citation>vanNimwegen KJ, van Soest RA, Veltman JA, et al. Is the $1000 genome as near as we think? a cost analysis of next-generation sequencing. Clin Chem. 2016;62:1458&#x2013;1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">27630156</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>